Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing ...

Learn how Mounjaro (tirzepatide) may reverse pre-diabetes in young adults in India, its benefits, and why early action is key.

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs in an attempt to curb their off-label ...